Global Tardive Dyskinesia Market
Global Tardive Dyskinesia Market

Tardive Dyskinesia Comprehensive Study by Application (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers), Treatment (Dopamine-Depleting Medications, GABA Receptor Agonist Medications, Anticholinergic Medications), Diagnosis (Blood Tests, CT Scan, MRI Scan) Players and Region - Global Market Outlook to 2024

Tardive Dyskinesia Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Aug 2019 Edition 246 Pages 195 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study
Tardive dyskinesia is a condition affecting the nervous system often long term use of some psychiatric drugs. It may appear as repetitive, jerking movements that occur in the face, neck and tongue. It can be very troubling for the patient. The long term use of medications called antipsychotics and some medications used for nausea can cause tardive dyskinesia. The one patient out of four who receive long term treatment with an antipsychotic will experience tardive dyskinesia. Elder people, females, diabetics and other mental illness are certain factors which increase the risk of tardive dyskinesia. There are many treatments available for tardive dyskinesia, but a response to the treatment depends on the patient.

The market study is being classified, by Application (Hospitals, Ambulatory Surgical Centers and Diagnostic Centers) and major geographies with country level break-up.

Teva Pharmaceutical Industries (Israel), Biogen (United States), Johnson and Johnson (United States), GlaxoSmithKline (United Kingdom), Neurocrine Biosciences (United States), Pfizer (United States), Novartis (Switzerland), Sanofi (France), AstraZeneca (United Kingdom) and Bayer AG (Germany) are some of the key players profiled in the study.

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Tardive Dyskinesia market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Tardive Dyskinesia market by Type, Application and Region.

On the basis of geography, the market of Tardive Dyskinesia has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Dopamine-Depleting Medications will boost the Tardive Dyskinesia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Blood Tests will boost the Tardive Dyskinesia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Number of Psychiatric Patients
  • Rising Number of Hospitals and Clinics

Market Trend
  • Increasing Research and Development Activities

Restraints
  • Expensive Treatment Options Available In the Market

Opportunities
  • Rising Use of Antipsychotic Drugs
  • Growing Geriatric Population Worldwide

Challenges
  • Lack of Awareness among People


Recently, the United States Food and Drug Administration approved Ingrezza (Valbenazine) capsules to treat adults with tardive dyskinesia. This was the first drug approved by the FDA for this condition.


Key Target Audience
Tardive Dyskinesia Treatment Providers, Emerging Companies, Research Institutes, Government Body & Associations and End-user

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Centers
By Treatment
  • Dopamine-Depleting Medications
  • GABA Receptor Agonist Medications
  • Anticholinergic Medications

By Diagnosis
  • Blood Tests
  • CT Scan
  • MRI Scan

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Psychiatric Patients
      • 3.2.2. Rising Number of Hospitals and Clinics
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness among People
    • 3.4. Market Trends
      • 3.4.1. Increasing Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tardive Dyskinesia, by Application, Treatment, Diagnosis and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Tardive Dyskinesia (Value)
      • 5.2.1. Global Tardive Dyskinesia by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Ambulatory Surgical Centers
        • 5.2.1.3. Diagnostic Centers
      • 5.2.2. Global Tardive Dyskinesia by: Treatment (Value)
        • 5.2.2.1. Dopamine-Depleting Medications
        • 5.2.2.2. GABA Receptor Agonist Medications
        • 5.2.2.3. Anticholinergic Medications
      • 5.2.3. Global Tardive Dyskinesia by: Diagnosis (Value)
        • 5.2.3.1. Blood Tests
        • 5.2.3.2. CT Scan
        • 5.2.3.3. MRI Scan
      • 5.2.4. Global Tardive Dyskinesia Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Tardive Dyskinesia: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva Pharmaceutical Industries (Israel)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Biogen (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson and Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Neurocrine Biosciences (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AstraZeneca (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bayer AG (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Tardive Dyskinesia Sale, by Application, Treatment, Diagnosis and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Tardive Dyskinesia (Value)
      • 7.2.1. Global Tardive Dyskinesia by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Ambulatory Surgical Centers
        • 7.2.1.3. Diagnostic Centers
      • 7.2.2. Global Tardive Dyskinesia by: Treatment (Value)
        • 7.2.2.1. Dopamine-Depleting Medications
        • 7.2.2.2. GABA Receptor Agonist Medications
        • 7.2.2.3. Anticholinergic Medications
      • 7.2.3. Global Tardive Dyskinesia by: Diagnosis (Value)
        • 7.2.3.1. Blood Tests
        • 7.2.3.2. CT Scan
        • 7.2.3.3. MRI Scan
      • 7.2.4. Global Tardive Dyskinesia Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tardive Dyskinesia: by Application(USD Million)
  • Table 2. Tardive Dyskinesia Hospitals , by Region USD Million (2013-2018)
  • Table 3. Tardive Dyskinesia Ambulatory Surgical Centers , by Region USD Million (2013-2018)
  • Table 4. Tardive Dyskinesia Diagnostic Centers , by Region USD Million (2013-2018)
  • Table 5. Tardive Dyskinesia: by Treatment(USD Million)
  • Table 6. Tardive Dyskinesia Dopamine-Depleting Medications , by Region USD Million (2013-2018)
  • Table 7. Tardive Dyskinesia GABA Receptor Agonist Medications , by Region USD Million (2013-2018)
  • Table 8. Tardive Dyskinesia Anticholinergic Medications , by Region USD Million (2013-2018)
  • Table 9. Tardive Dyskinesia: by Diagnosis(USD Million)
  • Table 10. Tardive Dyskinesia Blood Tests , by Region USD Million (2013-2018)
  • Table 11. Tardive Dyskinesia CT Scan , by Region USD Million (2013-2018)
  • Table 12. Tardive Dyskinesia MRI Scan , by Region USD Million (2013-2018)
  • Table 13. South America Tardive Dyskinesia, by Country USD Million (2013-2018)
  • Table 14. South America Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 15. South America Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 16. South America Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 17. Brazil Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 18. Brazil Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 19. Brazil Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 20. Argentina Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 21. Argentina Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 22. Argentina Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 23. Rest of South America Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 24. Rest of South America Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 25. Rest of South America Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 26. Asia Pacific Tardive Dyskinesia, by Country USD Million (2013-2018)
  • Table 27. Asia Pacific Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 28. Asia Pacific Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 29. Asia Pacific Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 30. China Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 31. China Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 32. China Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 33. Japan Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 34. Japan Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 35. Japan Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 36. India Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 37. India Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 38. India Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 39. South Korea Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 40. South Korea Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 41. South Korea Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 42. Taiwan Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 43. Taiwan Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 44. Taiwan Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 45. Australia Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 46. Australia Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 47. Australia Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 48. Rest of Asia-Pacific Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 49. Rest of Asia-Pacific Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 50. Rest of Asia-Pacific Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 51. Europe Tardive Dyskinesia, by Country USD Million (2013-2018)
  • Table 52. Europe Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 53. Europe Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 54. Europe Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 55. Germany Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 56. Germany Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 57. Germany Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 58. France Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 59. France Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 60. France Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 61. Italy Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 62. Italy Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 63. Italy Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 64. United Kingdom Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 65. United Kingdom Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 66. United Kingdom Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 67. Netherlands Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 68. Netherlands Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 69. Netherlands Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 70. Rest of Europe Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 71. Rest of Europe Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 72. Rest of Europe Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 73. MEA Tardive Dyskinesia, by Country USD Million (2013-2018)
  • Table 74. MEA Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 75. MEA Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 76. MEA Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 77. Middle East Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 78. Middle East Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 79. Middle East Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 80. Africa Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 81. Africa Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 82. Africa Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 83. North America Tardive Dyskinesia, by Country USD Million (2013-2018)
  • Table 84. North America Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 85. North America Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 86. North America Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 87. United States Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 88. United States Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 89. United States Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 90. Canada Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 91. Canada Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 92. Canada Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 93. Mexico Tardive Dyskinesia, by Application USD Million (2013-2018)
  • Table 94. Mexico Tardive Dyskinesia, by Treatment USD Million (2013-2018)
  • Table 95. Mexico Tardive Dyskinesia, by Diagnosis USD Million (2013-2018)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Tardive Dyskinesia: by Application(USD Million)
  • Table 107. Tardive Dyskinesia Hospitals , by Region USD Million (2019-2024)
  • Table 108. Tardive Dyskinesia Ambulatory Surgical Centers , by Region USD Million (2019-2024)
  • Table 109. Tardive Dyskinesia Diagnostic Centers , by Region USD Million (2019-2024)
  • Table 110. Tardive Dyskinesia: by Treatment(USD Million)
  • Table 111. Tardive Dyskinesia Dopamine-Depleting Medications , by Region USD Million (2019-2024)
  • Table 112. Tardive Dyskinesia GABA Receptor Agonist Medications , by Region USD Million (2019-2024)
  • Table 113. Tardive Dyskinesia Anticholinergic Medications , by Region USD Million (2019-2024)
  • Table 114. Tardive Dyskinesia: by Diagnosis(USD Million)
  • Table 115. Tardive Dyskinesia Blood Tests , by Region USD Million (2019-2024)
  • Table 116. Tardive Dyskinesia CT Scan , by Region USD Million (2019-2024)
  • Table 117. Tardive Dyskinesia MRI Scan , by Region USD Million (2019-2024)
  • Table 118. South America Tardive Dyskinesia, by Country USD Million (2019-2024)
  • Table 119. South America Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 120. South America Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 121. South America Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 122. Brazil Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 123. Brazil Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 124. Brazil Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 125. Argentina Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 126. Argentina Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 127. Argentina Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 128. Rest of South America Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 129. Rest of South America Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 130. Rest of South America Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 131. Asia Pacific Tardive Dyskinesia, by Country USD Million (2019-2024)
  • Table 132. Asia Pacific Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 133. Asia Pacific Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 134. Asia Pacific Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 135. China Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 136. China Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 137. China Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 138. Japan Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 139. Japan Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 140. Japan Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 141. India Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 142. India Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 143. India Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 144. South Korea Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 145. South Korea Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 146. South Korea Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 147. Taiwan Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 148. Taiwan Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 149. Taiwan Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 150. Australia Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 151. Australia Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 152. Australia Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 153. Rest of Asia-Pacific Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 154. Rest of Asia-Pacific Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 155. Rest of Asia-Pacific Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 156. Europe Tardive Dyskinesia, by Country USD Million (2019-2024)
  • Table 157. Europe Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 158. Europe Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 159. Europe Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 160. Germany Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 161. Germany Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 162. Germany Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 163. France Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 164. France Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 165. France Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 166. Italy Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 167. Italy Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 168. Italy Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 169. United Kingdom Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 170. United Kingdom Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 171. United Kingdom Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 172. Netherlands Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 173. Netherlands Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 174. Netherlands Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 175. Rest of Europe Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 176. Rest of Europe Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 177. Rest of Europe Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 178. MEA Tardive Dyskinesia, by Country USD Million (2019-2024)
  • Table 179. MEA Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 180. MEA Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 181. MEA Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 182. Middle East Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 183. Middle East Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 184. Middle East Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 185. Africa Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 186. Africa Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 187. Africa Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 188. North America Tardive Dyskinesia, by Country USD Million (2019-2024)
  • Table 189. North America Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 190. North America Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 191. North America Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 192. United States Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 193. United States Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 194. United States Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 195. Canada Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 196. Canada Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 197. Canada Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 198. Mexico Tardive Dyskinesia, by Application USD Million (2019-2024)
  • Table 199. Mexico Tardive Dyskinesia, by Treatment USD Million (2019-2024)
  • Table 200. Mexico Tardive Dyskinesia, by Diagnosis USD Million (2019-2024)
  • Table 201. Research Programs/Design for This Report
  • Table 202. Key Data Information from Secondary Sources
  • Table 203. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tardive Dyskinesia: by Application USD Million (2013-2018)
  • Figure 5. Global Tardive Dyskinesia: by Treatment USD Million (2013-2018)
  • Figure 6. Global Tardive Dyskinesia: by Diagnosis USD Million (2013-2018)
  • Figure 7. South America Tardive Dyskinesia Share (%), by Country
  • Figure 8. Asia Pacific Tardive Dyskinesia Share (%), by Country
  • Figure 9. Europe Tardive Dyskinesia Share (%), by Country
  • Figure 10. MEA Tardive Dyskinesia Share (%), by Country
  • Figure 11. North America Tardive Dyskinesia Share (%), by Country
  • Figure 12. Global Tardive Dyskinesia share by Players 2018 (%)
  • Figure 13. Global Tardive Dyskinesia share by Players (Top 3) 2018(%)
  • Figure 14. Global Tardive Dyskinesia share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Teva Pharmaceutical Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 17. Teva Pharmaceutical Industries (Israel) Revenue: by Geography 2018
  • Figure 18. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 19. Biogen (United States) Revenue: by Geography 2018
  • Figure 20. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 21. Johnson and Johnson (United States) Revenue: by Geography 2018
  • Figure 22. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2018
  • Figure 24. Neurocrine Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 25. Neurocrine Biosciences (United States) Revenue: by Geography 2018
  • Figure 26. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer (United States) Revenue: by Geography 2018
  • Figure 28. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis (Switzerland) Revenue: by Geography 2018
  • Figure 30. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 31. Sanofi (France) Revenue: by Geography 2018
  • Figure 32. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. AstraZeneca (United Kingdom) Revenue: by Geography 2018
  • Figure 34. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Bayer AG (Germany) Revenue: by Geography 2018
  • Figure 36. Global Tardive Dyskinesia: by Application USD Million (2019-2024)
  • Figure 37. Global Tardive Dyskinesia: by Treatment USD Million (2019-2024)
  • Figure 38. Global Tardive Dyskinesia: by Diagnosis USD Million (2019-2024)
  • Figure 39. South America Tardive Dyskinesia Share (%), by Country
  • Figure 40. Asia Pacific Tardive Dyskinesia Share (%), by Country
  • Figure 41. Europe Tardive Dyskinesia Share (%), by Country
  • Figure 42. MEA Tardive Dyskinesia Share (%), by Country
  • Figure 43. North America Tardive Dyskinesia Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Teva Pharmaceutical Industries (Israel)
  • Biogen (United States)
  • Johnson and Johnson (United States)
  • GlaxoSmithKline (United Kingdom)
  • Neurocrine Biosciences (United States)
  • Pfizer (United States)
  • Novartis (Switzerland)
  • Sanofi (France)
  • AstraZeneca (United Kingdom)
  • Bayer AG (Germany)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation